Skip to main content
TipRanks
Go Ultimate75% OFF

Oncolys BioPharma, Inc. (4588) Stock Statistics & Valuation Metrics

1 Followers

Total Valuation

Oncolys BioPharma, Inc. has a market cap or net worth of JPY 225.09B. The enterprise value is JPY 171.91B.

Market Cap
JPY 225.09B
Enterprise Value
JPY 171.91B

Share Statistics

Oncolys BioPharma, Inc. has 29,575,700 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
29,575,700
Owned by Insiders
―
Owned by Institutions
0.10%

Financial Efficiency

Oncolys BioPharma, Inc.’s return on equity (ROE) is -0.51 and return on invested capital (ROIC) is -46.76%.

Return on Equity (ROE)
-0.51
Return on Assets (ROA)
-0.45
Return on Invested Capital (ROIC)
-46.76%
Return on Capital Employed (ROCE)
-0.50
Revenue Per Employee
679.67K
Profits Per Employee
-49.00M
Employee Count
42
Asset Turnover
0.01
Inventory Turnover
0.06

Valuation Ratios

The current PE Ratio of Oncolys BioPharma, Inc. is -138.17. Oncolys BioPharma, Inc.’s PEG ratio is -3.50.

PE Ratio
-138.17
PS Ratio
425.04
PB Ratio
72.43
Price to FCF
0.00
Price to Operating Cash Flow
0.00
PEG Ratio
-3.50

Income Statement

In the last 12 months, Oncolys BioPharma, Inc. had revenue of 28.55M and earned -2.06B in profits. Earnings per share was -80.00.

Revenue
28.55M
Gross Profit
28.30M
Operating Income
-2.02B
Pretax Income
-2.05B
Net Income
-2.06B
EBITDA
-2.05B
Earnings Per Share (EPS)
-80.00

Cash Flow

In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0 billion.

Operating Cash Flow
0
Free Cash Flow
0
Free Cash Flow per Share
0.00

Dividends & Yields

Oncolys BioPharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
0.00%
Earnings Yield
-0.70%

Stock Price Statistics

Beta
1.96
52-Week Price Change
613.48%
50-Day Moving Average
6426.80
200-Day Moving Average
3683.88
Relative Strength Index (RSI)
55.94
Average Volume (3m)
1.76M

Important Dates

Oncolys BioPharma, Inc. upcoming earnings date is Feb 05, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 06, 2026
Next Earnings Date
Feb 05, 2027
Ex-Dividend Date
―

Financial Position

Oncolys BioPharma, Inc. as a current ratio of 9.55, with Debt / Equity ratio of 8.00%

Current Ratio
9.55
Quick Ratio
9.54
Debt to Market Cap
0.01
Net Debt to EBITDA
1.64
Interest Coverage Ratio
-386.72

Taxes

In the past 12 months, Oncolys BioPharma, Inc. has paid 4.03M in taxes.

Income Tax
4.03M
Effective Tax Rate
-0.00

Enterprise Valuation

Oncolys BioPharma, Inc. EV to EBITDA ratio is -143.68, with an EV/FCF ratio of 0.00.

EV to Sales
419.81
EV to EBITDA
-143.68
EV to Free Cash Flow
0.00
EV to Operating Cash Flow
0.00

Balance Sheet

Oncolys BioPharma, Inc. has JPY 3.72B in cash and marketable securities with JPY 320.02M in debt, giving a net cash position of JPY 3.40B billion.

Cash & Marketable Securities
JPY 3.72B
Total Debt
JPY 320.02M
Net Cash
JPY 3.40B
Net Cash Per Share
JPY 115.02
Tangible Book Value Per Share
JPY 155.49

Margins

Gross margin is 99.94%, with operating margin of -295.09%, and net profit margin of -294.82%.

Gross Margin
99.94%
Operating Margin
-295.09%
Pretax Margin
-293.95%
Net Profit Margin
-294.82%
EBITDA Margin
-292.18%
EBIT Margin
-292.25%

Analyst Forecast

The average price target for Oncolys BioPharma, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
1748.97%
EPS Growth Forecast
35.11%

Scores

Smart Score
―
AI Score
50